Lantheus Holdings (LNTH) Common Equity (2014 - 2026)
Lantheus Holdings' (LNTH) quarterly Common Equity came in at $1.2 billion in Q1 2026, up 4.13% year-on-year from $1.2 billion in Q1 2025, and up 11.24% on a QoQ basis from $1.1 billion in Q4 2025.
Lantheus Holdings (LNTH) Common Equity (2014 - 2026) Analysis & Trends
Lantheus Holdings (LNTH) has 13 years of Common Equity data on file, last reported at $1.2 billion in Q1 2026.
- On a quarterly basis, Common Equity rose 4.13% year-over-year to $1.2 billion in Q1 2026; TTM through Mar 2026 was $1.2 billion, a 4.13% increase from a year earlier, with the FY2025 full-year figure at $1.1 billion, changed 0.16% from the prior year.
- Common Equity for Q1 2026 stood at $1.2 billion, up from $1.1 billion in the prior quarter.
- Over the last five years, Common Equity for LNTH reached as high as $1.2 billion in Q1 2026 and fell as low as $445.5 million in Q1 2023.
- Historically, Common Equity has averaged $863.1 million across 5 years, with a median of $945.5 million in 2024.
- Across the five-year window, Common Equity fell 13.63% in 2023 and surged 112.23% in 2024, its largest moves.
- Year by year, Common Equity stood at $447.1 million in 2022, then surged by 82.47% to $815.9 million in 2023, then soared by 33.35% to $1.1 billion in 2024, then rose by 0.16% to $1.1 billion in 2025, then rose by 11.24% to $1.2 billion in 2026.
- Per Business Quant data, the three most recent Common Equity figures were $1.2 billion in Q1 2026, $1.1 billion in Q4 2025, and $1.1 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 21.93 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 8.23 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 3.23 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 47.38 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 5.90 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 56.13 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 14.66 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 3.41 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 6.50 Bn |
| 10 | Lantheus Holdings | 6.72 Bn | 6.22 Bn | 230.92 Mn | 1.21 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.21 Bn |
| Dec 31, 2025 | 1.09 Bn |
| Sep 30, 2025 | 1.12 Bn |
| Jun 30, 2025 | 1.17 Bn |
| Mar 31, 2025 | 1.16 Bn |
| Dec 31, 2024 | 1.09 Bn |
| Sep 30, 2024 | 1.18 Bn |
| Jun 30, 2024 | 1.03 Bn |
| Mar 31, 2024 | 945.54 Mn |
| Dec 31, 2023 | 815.89 Mn |
| Sep 30, 2023 | 698.76 Mn |
| Jun 30, 2023 | 552.65 Mn |
| Mar 31, 2023 | 445.52 Mn |
| Dec 31, 2022 | 447.15 Mn |
| Sep 30, 2022 | 638.05 Mn |
| Jun 30, 2022 | 567.33 Mn |
| Mar 31, 2022 | 515.85 Mn |
| Dec 31, 2021 | 464.44 Mn |
| Sep 30, 2021 | 499.34 Mn |
| Jun 30, 2021 | 508.14 Mn |